376 related articles for article (PubMed ID: 30064826)
1. Immunosuppression, Race, and Donor-Related Risk Factors Affect De novo Cancer Incidence Across Solid Organ Transplant Recipients.
Bhat M; Mara K; Dierkhising R; Watt KDS
Mayo Clin Proc; 2018 Sep; 93(9):1236-1246. PubMed ID: 30064826
[TBL] [Abstract][Full Text] [Related]
2. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
Kauffman HM; Cherikh WS; Cheng Y; Hanto DW; Kahan BD
Transplantation; 2005 Oct; 80(7):883-9. PubMed ID: 16249734
[TBL] [Abstract][Full Text] [Related]
3. Spectrum of De Novo Cancers and Predictors in Liver Transplantation: Analysis of the Scientific Registry of Transplant Recipients Database.
Zhou J; Hu Z; Zhang Q; Li Z; Xiang J; Yan S; Wu J; Zhang M; Zheng S
PLoS One; 2016; 11(5):e0155179. PubMed ID: 27171501
[TBL] [Abstract][Full Text] [Related]
4.
Manzia TM; Angelico R; Gazia C; Lenci I; Milana M; Ademoyero OT; Pedini D; Toti L; Spada M; Tisone G; Baiocchi L
World J Gastroenterol; 2019 Sep; 25(35):5356-5375. PubMed ID: 31558879
[TBL] [Abstract][Full Text] [Related]
5. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
[TBL] [Abstract][Full Text] [Related]
6. Temporal Trends of De Novo Malignancy Development After Heart Transplantation.
Youn JC; Stehlik J; Wilk AR; Cherikh W; Kim IC; Park GH; Lund LH; Eisen HJ; Kim DY; Lee SK; Choi SW; Han S; Ryu KH; Kang SM; Kobashigawa JA
J Am Coll Cardiol; 2018 Jan; 71(1):40-49. PubMed ID: 29301626
[TBL] [Abstract][Full Text] [Related]
7. National survey of de novo malignancy after solid organ transplantation in Japan.
Miyazaki T; Sato S; Kondo T; Kusaka M; Gotoh M; Saiki Y; Ono M; Kokudo N; Enosawa S; Satoh S; Soeda E; Furukawa H; Kobayashi E; Nagayasu T
Surg Today; 2018 Jun; 48(6):618-624. PubMed ID: 29380136
[TBL] [Abstract][Full Text] [Related]
8. Nationwide population-based study reveals increased malignancy risk in taiwanese liver transplant recipients.
Tsai YF; Chen HP; Liu FC; Liu SH; Chen CY; Cheng CW; Lin JR
Oncotarget; 2016 Dec; 7(50):83784-83794. PubMed ID: 27626495
[TBL] [Abstract][Full Text] [Related]
9. De Novo Malignancy After Heart, Kidney, and Liver Transplant: A Nationwide Study in Taiwan.
Yeh CC; Khan A; Muo CH; Yang HR; Li PC; Chang CH; Chen TL; Jeng LB; Liao CC
Exp Clin Transplant; 2020 Apr; 18(2):224-233. PubMed ID: 32133940
[TBL] [Abstract][Full Text] [Related]
10. Association of HLA Antigen Mismatch With Risk of Developing Skin Cancer After Solid-Organ Transplant.
Gao Y; Twigg AR; Hirose R; Roll GR; Nowacki AS; Maytin EV; Vidimos AT; Rajalingam R; Arron ST
JAMA Dermatol; 2019 Mar; 155(3):307-314. PubMed ID: 30673077
[TBL] [Abstract][Full Text] [Related]
11. De novo malignancy in heart transplant recipients: A single center experience in Japan.
Kimura Y; Yanase M; Mochizuki H; Iwasaki K; Toda K; Matsuda S; Takenaka H; Kumai Y; Kuroda K; Nakajima S; Watanabe T; Ikura MM; Wada K; Matsumoto Y; Seguchi O; Fukushima S; Fujita T; Kobayashi J; Fukushima N
J Cardiol; 2019 Mar; 73(3):255-261. PubMed ID: 30587457
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
Opelz G; Unterrainer C; Süsal C; Döhler B
Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
[TBL] [Abstract][Full Text] [Related]
13. De novo malignancies after intestinal and multivisceral transplantation.
Abu-Elmagd KM; Zak M; Stamos JM; Bond GJ; Jain A; Youk AO; Ezzelarab M; Costa G; Wu T; Nalesnik MA; Mazariegos GV; Sindhi RK; Marcos A; Demetris AJ; Fung JJ; Reyes JD
Transplantation; 2004 Jun; 77(11):1719-25. PubMed ID: 15201672
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.
Gutierrez-Dalmau A; Campistol JM
Drugs; 2007; 67(8):1167-98. PubMed ID: 17521218
[TBL] [Abstract][Full Text] [Related]
15. The 28-year incidence of de novo malignancies after liver transplantation: A single-center analysis of risk factors and mortality in 1616 patients.
Rademacher S; Seehofer D; Eurich D; Schoening W; Neuhaus R; Oellinger R; Denecke T; Pascher A; Schott E; Sinn M; Neuhaus P; Pratschke J
Liver Transpl; 2017 Nov; 23(11):1404-1414. PubMed ID: 28590598
[TBL] [Abstract][Full Text] [Related]
16. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past.
Wang EH; Partovi N; Levy RD; Shapiro RJ; Yoshida EM; Greanya ED
Transpl Infect Dis; 2012 Oct; 14(5):519-25. PubMed ID: 22571389
[TBL] [Abstract][Full Text] [Related]
17. "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation".
Wareham NE; Li Q; Sengeløv H; Da Cunha-Bang C; Gustafsson F; Heilmann C; Perch M; Rasmussen A; Sørensen SS; Mocroft A; Lundgren JD
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3125-3135. PubMed ID: 31587105
[TBL] [Abstract][Full Text] [Related]
18. Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.
Aguiar D; Martínez-Urbistondo D; D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Sangro B; Quiroga J; Herrero JI
Ann Transplant; 2017 Mar; 22():141-147. PubMed ID: 28302995
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of cancer risk among US solid organ transplant recipients.
Engels EA; Pfeiffer RM; Fraumeni JF; Kasiske BL; Israni AK; Snyder JJ; Wolfe RA; Goodrich NP; Bayakly AR; Clarke CA; Copeland G; Finch JL; Fleissner ML; Goodman MT; Kahn A; Koch L; Lynch CF; Madeleine MM; Pawlish K; Rao C; Williams MA; Castenson D; Curry M; Parsons R; Fant G; Lin M
JAMA; 2011 Nov; 306(17):1891-901. PubMed ID: 22045767
[TBL] [Abstract][Full Text] [Related]
20. Early immunosuppression treatment correlates with later de novo donor-specific antibody development after kidney and pancreas transplantation.
Pelletier RP; Rajab AA; Diez A; DiPaola NR; Bumgardner GL; Elkhammas EA; Henry ML
Clin Transplant; 2015 Dec; 29(12):1119-27. PubMed ID: 26382932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
